GPR21

GPR21 is a constitutively active class-A orphan G protein-coupled receptor that functions as a negative regulator of insulin signaling and hepatic glucose uptake. Its extracellular loop 2 (ECL2) serves as an intrinsic agonist-like motif that occupies the orthosteric pocket to drive ligand-independent coupling to Gαq, Gαs, and G15, activating MAPK signaling and suppressing AKT/GSK-3β-mediated insulin signaling and GLUT-2 surface expression in hepatocytes (PMID:36639690, PMID:36721851, PMID:27243589, PMID:34639123). In vivo, GPR21 deletion improves insulin sensitivity, glucose tolerance, and reduces inflammatory markers, while in immune cells GPR21 regulates monocyte polarization and MCP-1-directed chemotaxis through a mechanism separable from its metabolic role (PMID:22155242, PMID:34782333). Prex1 maintains GPR21 at the hepatocyte plasma membrane through an adaptor function independent of its GEF activity, and this surface retention is required for GPR21-mediated suppression of glucose uptake and mitochondrial ATP production [PMID:bio_10.1101_2025.04.14.648781].

1. 2011 Medium

   The first loss-of-function study established that GPR21 is not merely an orphan receptor but an in vivo regulator of body weight, glucose homeostasis, and systemic inflammation, providing the rationale for investigating its signaling mechanism.

   Evidence GPR21-knockout mice on high-fat diet showed reduced adiposity, improved insulin sensitivity, improved glucose tolerance, and decreased circulating MCP-1/CRP/IP-10

   PMID:22155242

   Open questions at the time

   • Possible co-deletion of neighboring gene Rabgap1 questioned specificity of metabolic phenotype
   • Cell-autonomous versus systemic contribution of GPR21 was not resolved
   • No signaling pathway was identified downstream of GPR21 in this study
2. 2016 Medium

   Demonstrating that GPR21 is constitutively active and couples to Gαq/MAPK signaling resolved the question of which G-protein pathway it engages and revealed that its activity directly antagonizes insulin signaling at the cellular level.

   Evidence Overexpression of GPR21 in HEK293T cells activated MAPKs and attenuated insulin signaling; serum reduced these effects, suggesting a possible inhibitory ligand

   PMID:27243589

   Open questions at the time

   • Constitutive activity was shown only by overexpression, not at endogenous expression levels
   • The putative serum-borne inhibitory ligand was not identified
   • Direct interaction between GPR21 and Gαq was not structurally confirmed
3. 2021 Medium

   Two studies in 2021 dissected the downstream mechanism in hepatocytes and separated GPR21's metabolic role from its immune-cell function: GPR21 suppresses hepatic glucose uptake by inhibiting AKT and GLUT-2 translocation, while in monocytes it regulates chemotaxis to MCP-1 via polarization control, independent of CCR2 expression or the metabolic pathway.

   Evidence siRNA knockdown and inverse agonist GRA2 in HepG2 cells increased glucose uptake, GLUT-2 surface levels, and pAKT while reducing pERK; selective KO mice combined with bone marrow transplantation showed non-overlapping immune and metabolic mechanisms

   PMID:34639123 PMID:34782333

   Open questions at the time

   • The molecular link between GPR21 and monocyte polarization machinery is unknown
   • GRA2 selectivity was not independently validated by an orthogonal binding assay
   • Whether GPR21 directly modulates GLUT-2 trafficking or acts indirectly through ERK/AKT balance is unresolved
4. 2023 High

   Cryo-EM structures of ligand-free GPR21 in complex with miniGs, miniG15, and Gαs answered how a receptor with no known agonist achieves constitutive activation: ECL2 folds into the orthosteric pocket as an intrinsic agonist-like element, and G-protein coupling occurs with minimal TM6 outward displacement, an atypical activation mechanism among class-A GPCRs.

   Evidence Cryo-EM single-particle analysis of GPR21–G-protein complexes, mutagenesis of ECL2 abolished cAMP production; a druggable side pocket was identified

   PMID:36639690 PMID:36721851

   Open questions at the time

   • No exogenous ligand or endogenous inhibitor has been identified that binds the side pocket
   • Structural basis for Gαq coupling was not captured (only miniGs and miniG15 complexes solved)
   • Whether ECL2 auto-agonism is regulated by post-translational modification or interacting proteins in vivo is unknown
5. 2025 Medium

   The discovery that Prex1 acts as a GEF-independent adaptor to retain GPR21 at the plasma membrane established the first upstream trafficking mechanism controlling GPR21 surface density and linked this to GPR21-dependent suppression of mitochondrial ATP production, a previously unrecognized downstream effect.

   Evidence Prex1 KO and catalytically-inactive knock-in mice; GPCR surface trafficking assays, mitochondrial membrane potential and ATP measurements, GLUT-2 surface quantification in hepatocytes (preprint)

   PMID:bio_10.1101_2025.04.14.648781

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Direct physical interaction interface between Prex1 and GPR21 has not been mapped
   • Whether Prex1-dependent trafficking applies in non-hepatic cell types (e.g., monocytes) is untested

• Major open questions include the identity of any endogenous ligand or inverse agonist for GPR21, the structural basis for Gαq coupling, and the molecular mechanism by which GPR21 controls monocyte polarization.
• No endogenous ligand or inverse agonist has been identified despite serum-dependent activity modulation
• Gαq-coupled cryo-EM structure has not been determined
• The link between GPR21 and monocyte polarization machinery is entirely uncharacterized at the molecular level